- Forcano, Laura
- Soldevila-Domenech, Natalia
- Boronat Rigol, Anna, 1990-
- Sánchez Benavides, Gonzalo
- Puig-Pijoan, Albert
- Lorenzo, Thais
- Aldea-Perona, Ana
- Suárez-Calvet, Marc
- Cuenca Royo, Aida Ma, 1981-
- Gispert, Juan Domingo
- Gomis González, Maria, 1988-
- Minguillón, Carolina
- Diaz-Pellicer, Patricia
- Piera, Iris
- Langohr, Klaus
- Dierssen, Mara
- Pizarro Lozano, Ma. Nieves
- Mur-Gimeno E.
- Grau, Oriol (Grau Rivera)
- Molinuevo, José Luis
- Torre Fornell, Rafael de la
- PENSA working group
Background: The potential of dietary compounds to enhance the effects of multimodal lifestyle interventions (MLIs) on cognition in individuals at high risk of cognitive impairment remains unclear. Objectives: To assess whether the addition of a green tea extract enriched with epigallocatechin-3-gallate (EGCG) enhances the effects of an MLI. Design: Double-blind, randomized, two-arm, and placebo-controlled trial. Exploratory comparisons were made with a non-randomized group (NRG) receiving healthy lifestyle recommendations. Setting: Population-based study conducted in Barcelona, Spain PARTICIPANTS: APOE-ɛ4 carriers aged 60-80 with subjective cognitive decline INTERVENTION: A 12-month intensive MLI including dietary counseling, guided physical activity, and cognitive stimulation, combined with EGCG (5-6 mg/kg) or placebo, followed by a 3-month washout. Measurements: Primary endpoint was change in the modified Preclinical Alzheimer Cognitive Composite (PACC-exe) score. Results: 129 participants (65.1% 84 women, aged 66.7±5.5 years) were enrolled (52 MLI+EGCG, 52 MLI+placebo and 25 NRG), with126 (97.7%) included in the modified intention-to-treat analysis. After 12 months, no statistically significant difference was observed between MLI+EGCG and MLI+placebo in the PACC-exe (adjusted mean difference [AMD]: 0.12; 95%CI: -0.01, 0.24; p=0.061). However, participants in the MLI+EGCG group were 2.6 times more likely to show a reliable cognitive improvement. In exploratory analyses following a 3-month washout, the MLI+EGCG group showed significant cognitive benefits compared to the MLI+placebo (AMD: 0.19; 95%CI: 0.06, 0.32; p=0.005). Exploratory comparisons with the NRG also suggested greater gains in cognition and dementia risk reduction in both MLI groups, particularly with EGCG. Conclusions: While the primary outcome was not met, this proof-of-concept trial suggests that combining MLIs with EGCG warrants further investigation in larger, confirmatory studies., This study was mainly funded by the Alzheimer¿s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer's disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated "Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs", supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea - FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication., This study was mainly funded by the Alzheimer’s Association, The PART THE CLOUD to RESCUE (REverse, reStore, Cease and UndErstand) Brain Cell Degeneration in Alzheimer’s disease Program, grant 18PTC-R-592192 and Project PI17/00223, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by European Regional Development Fund (FEDER). RdlT leads the Consolidated “Clinical Research Group in Pharmacology and Development of Biomarkers and New Drugs”, supported by the Generalitat de Catalunya (2021 SGR 00253 and 2021 SGR 01421). This research was also supported by CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/03/0028), Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades (PID2022-141900OB-I00; PID2023-148033OB-C21) and Unión Europea – FEDER Fund; Grant AC22/00004 funded by Instituto de Salud Carlos III, and by the European Union NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia (MultiMemo, JPND program); and by the "Responsible Research and Innovation Awards" (RRI20/00005) organized by the ISCIII and promoted within the framework of the European project ORION (Open Responsible research and Innovation to further Outstanding kNowledge). NS-D had a predoctoral fellowship (2022 FI_B1 00026) from AGAUR-Generalitat de Catalunya, and TL had a predoctoral fellowship FI18/00041 from the ISCIII. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.